Compile Data Set for Download or QSAR
maximum 50k data
Found 302 Enz. Inhib. hit(s) with all data for entry = 8754
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417008((+)-N-(5-(1-amino-1-(6-cyanopyridin-2-yl)-3-cyclop...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417009(1-(3-carbamimidoylphenyl)-N-(5-((+-)-3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417012((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417013(1-(1-aminoisoquinolin-7-yl)-N-(5-(3-cyclopropyl-1-...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417014((+-)-N-(5-(1-amino-1-(3-carbamoylphenyl)-3-cyclopr...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417016((+)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417018((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-3-yl)pr...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417019((+)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417020(HCl salt of (+-)-1-(3-carbamimidoylphenyl)-N-(5-((...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417021((+)-5-(1-amino-1-(3-(1-(3-(aminomethyl)phenyl)-3-(...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417022((+)-1-(1-aminoisoquinolin-7-yl)-N-(5-((cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417023((+)-N-(5-(1-amino-1-(4-carbamoylphenyl)-3-cyclopro...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417024((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-4-yl)pr...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417025((+)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417026((+-)-1-(3-(aminomethyl)phenyl)-N5-(5-((cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417027(1-(3-(aminomethyl)phenyl)-N-(5-((+-)-3-cyclopropyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417028(1-(1-aminoisoquinolin-7-yl)-N-(5-(3-cyclopropyl-1-...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417032(1-(1-aminoisoquinolin-7-yl)-N-(5-(3-cyclopropyl-1-...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416739(1-(3-(aminomethyl)phenyl)-N-(3-((2-cyclopropylethy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416742(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416745(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416747(1-(3-(Aminomethyl)phenyl)-N-(5-((cyclopropylmethox...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416748(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416751(Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416757(1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-(1...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416760((E/Z)-1-(3-(Aminomethyl)phenyl)-N-(3-(3-cyclopropy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416763(1-(3-(Aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416764(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416766(1-(3-(aminomethyl)phenyl)-N-(3-((2-cyclopropyletho...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416767(1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-hy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416770(Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416773(1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416774(1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-hy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416775(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416777(1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416779(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416780(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416782(1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416783(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416784(1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416785(1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416786(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416787(1-(3-(aminomethyl)phenyl)-N-(3-cyclopropyl-5-((cyc...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416788(1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416789(1-(3-(aminomethyl)phenyl)-N-(5-((4-aminophenyl)(cy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416790(1-(3-(Aminomethyl)phenyl)-N-(2-chloro-5-((cyclopro...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416791(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416792(1-(3-(aminomethyl)phenyl)-N-(5-((3-aminophenyl)(cy...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM416794(Racemic 1-(3-(aminomethyl)phenyl)-N-(5-((cycloprop...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 302 total ) | Next | Last >>
Jump to: